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The increase in production of Extended Spectrum Beta Lactamase (ESBL) and Amp C beta lactamase among clinical isolates in 
our hospitals is of utmost importance.   Failure to detect these enzymes in many of our hospitals has greatly led to treatment 
failure and uncontrolled spread of multi drug resistant pathogens. It was for this purpose that the present study was conducted 
to determine the prevalence, distribution and susceptibility pattern of Gram negative bacteria producing ESBLs and Amp C 
beta lactamases in the largest tertiary health care provider in Kano, North-West Nigeria. A total of 75 ESBL and 10 AmpC 
producing bacteria were involved in the study which were obtained from a study involving 500 Gram negative clinical bacterial 
isolates  from various hospital wards over a period of 9 months  from Aminu Kano Teaching Hospital (AKTH), Kano, Nigeria. 
Isolates were screened for ESBLs and AmpC using Double Disc Diffusion Method and Amp C Disc test respectively. All 
confirmed ESBL and Amp C producing isolates were tested for susceptibility to sixteen (16) different antibiotics by the Disc 
Diffusion Method (DDM).  The prevalence of ESBLs was high in Shigella spp. (1/2 or 50%), followed by Klebsiella pneumoniae 
(10/50 or /20%), and E. coli (47/247 or 19.3%) while Amp C producers were detected more in Klebsiella pneumoniae (4%) and E. 
coli (2.8%). Of the specimens screened, distribution varies between ESBL and AmpC producers, but more prevalent in urinary 
tract pathogens in both. Highest prevalence of ESBLs and AmpC producers was recorded in intensive care units and surgical 
wards. ESBL and AmpC production in the hospital is not sex dependent statistically, thought higher in males (52 and 60%) than 
in females  (48 and 40%) for  ESBL and AmpC respectively.  ESBL and AmpC producers were both sensitive  to Imipenem, 
Nitrofurantoin  and  Levofloxacin  and  resistance  to  Amoxycillin,  Ceftazidime  and  Tetracycline.  The  study  indicates  the 
occurrence of ESBL and AmpC producers in our tertiary health provider, widely distributed in various clinical samples, wards 
and sexes and are multi drug resistant posing serious threat in managing life threatening infections. 
 




Beta lactamases are enzymes produced by some 
bacteria and are responsible for their resistance to ß- 
lactam antibiotics like penicillins, cephamycin and 
carbapenem  [1].  β-lactamase  deactivates  the 
molecular antibacterial properties of β-lactam 
antibiotics   there   by   breaking   and   opening   the 
common element in their molecular structure β- 
lactam. Some of these enzymes include extended 
spectrum β-lactamase (ESBL), AmpC βL, and 
carbapenemase. The  first  β-lactamase was  detected 
during the  1960s [2].  Since  then  many types  of  β- 
lactamases   which   vary   both   in   their   ability   to 
inactivate a given beta lactam drug as well as their 
susceptibility to  inhibitors  such  as  clavulanic  acid, 
sulbactam and tazobactam came into existence. 
 
Extended spectrum beta lactamases (ESBLs) are 
enzymes that  mediate resistance to  the  third 
generation  cephalosporins  (e.g  ceftazidime, 
cefotaxime  and  ceftriaxone)  and  monobactams (e.g 
aztreonem) but do not affect cephamycins. The 
enzymes are now observed worldwide in all species 
of  Enterobacteriaceae especially  K.  pneumoniae  and 
Escherichia   coli.   Originally,   ESBL   enzymes   were 
derived from the widespread TEM and SHV β- 
lactamase  family.  The  first  β-lactamase  with  an 





[3] and later in the western parts of Europe, probably 
because expanded-spectrum β-lactam antibiotics were 
first used their clinically. 
 
The Class C β-lactamases (AmpC) are an important 
group of proteins that are broadly distributed and are 
the second most common β-lactamase group [1]. 
AmpC β-lactamases, in contrast to ESBLs, hydrolyse 
broad and extended-spectrum cephalosporins but are 
resistant to inhibition by β-lactamase inhibitors such 
as clavulanic acid [4,5,6]. 
 
In Nigeria, indiscriminate use of antibiotics, poor 
hygienic practices in hospitals and lack of monitoring 
of microbial drug resistance have created suitable 
conditions for the emergency and uncontrollable 
spread of the ESBLs and Amp C enzymes [7]   and 
thus  make their    detection complicated due  to  the 
variable affinity of these enzymes for different 
substrates and inoculum effect. 
 
Resistant   to   commonly   used   antibiotics   in   our 
hospitals increases at an alarming rate. Awareness of 
their   occurrence   and   their   potential   effects   in 
managing infectious diseases is low among the health 
care providers. Laboratory detections of these 
enzymes, proper reporting, necessary precautions to 
avoid their spread is lacking in many of our hospitals. 
In view of this, the research was conducted to detect 
the prevalence, distribution and antibiotic 
susceptibility of ESBL and AmpC producing clinical 
isolates in a tertiary health care provider which serves 
as a referral centers for other hospital in the region. 
 
MATERIALS AND METHODS 
Collection of specimens 
A  total  of  eighty five  (85)  Gram  negative bacterial 
isolates comprising of 75 ESBL and 10 AmpC 
producing isolates were involved in  the study. The 
screening was done in a study involving 500 clinical 
isolates collected from various clinical samples and 
hospital  wards  of  the  Microbiology Department of 
Aminu Kano Teaching Hospital (AKTH), Kano, 
Nigeria. The isolates were identified according to the 
procedures described by Cheesbrough [8]. Ethical 
clearance was granted to conduct the research by the 
management of the hospital. 
Presumptive Test for ESBLs 
 
All the clinical isolates collected were tested for 
potential ESBL producers using the Cefpodoxime 
(10µg) and the Ceftriaxone (30µg) antibiotic discs. 
Results were interpreted based on the CLSI criteria 
[9]. 
 
Confirmatory Test for ESBLs 
 
All isolates suspected of ESBL production in the 
presumptive test were furthered confirmed using the 
double discs  synergy according to  CLSI  guidelines 
[9]. A suspension of the test organism was inoculated 
on Mueller- Hinton agar. A disc containing 30µg 
Amoxicillin plus clavulanic acid was placed centrally 
on  the  plate.  Discs  containing cefpodoxime (10µg) 
and ceftriaxone (30µg) were placed on the agar at a 
distance of  15mm, centre  to  centre away from  the 
amoxicillin +  clavulanic acid disk. The plates were 
incubated over night at 35°C. The results were then 
interpreted as outlined in the CLSI guidelines [9]. A ≥ 
5-mm    increase    in    zone    diameter    for    either 
antimicrobial agent combination compared to its zone 
when tested alone signified a positive ESBL. 
 
PRESUMPTION TEST FOR Amp C 
 
Sensitivity cefoxitin (30µg) discs were used to test for 
Amp C production using the disc diffusion method 
and interpreted as per the CLSI criteria [9]. Isolates 
that yielded a zone diameter less than 18 mm (screen 
positive) were further subjected to confirmatory test 
using the AmpC disc test technique. 
 
AMP C DISK TEST 
 
All confirmed isolates from the presumptive test were 
then subjected to the Amp C disc test as described by 
black et al [10]. A lawn culture of E. coli ATCC 25922 
was prepared on  MHA plate. Sterile disks (6  mm) 
were moistened with sterile saline (20µl) and 
inoculated with several colonies of test organism. The 
inoculated disk was  then  placed beside a  cefoxitin 
disk (almost touching) on the inoculated plate. The 
plates were incubated overnight at 35°C. A positive 
test  appeared as  a  flattening or  indentation of  the 
cefoxitin inhibition zone  in  the  vicinity of  the  test 






ANTIMICROBIAL SUSCEPTIBILITY TESTING 
 
Antibiotic susceptibility tests were performed on all 
the confirmed ESBLS and Amp C Beta lactamase 
positive isolates according to CLSI directives [9]. The 
results were expressed as susceptible or resistant 
according to criteria developed by CLSI [9]. Sixteen 
(16) different antibiotic discs (Oxoid) were used : 
Gentamicin (10µg), Cotrimoxazole (25µg), 
Ciprofloxacin  (5µg),  Cefpodoxime  (30µg), 
Ceftazidime (30µg), Ceftriaxone (30µg), Cefoxitin 
(30µg), Imipenem (10µg) Nalidixic Acid (30µg), 
Amoxycillin (20µg),  Ofloxacin (30µg),  Levofloxacin 
(30µg), Nitrofurantoin  (300µg), Tetracycline (30µg), 
Chlorampenicol (30µg) and Augmentin (30µg) 
(Oxoid). Escherichia coli ATCC 25922 strain was used 




ESBL Producing Isolates 
Out of the 500 isolates screened for ESBL production, 
75 were confirmed to produce ESBL giving an overall 
prevalence of 15.0%. The highest prevalence of ESBLs 
was found in Shigella spp (1/2 or 50%) followed by 
Klebsiella pneumoniae (10/50 or 20.0%), E. coli (47/247 
or   19.3%),   Salmonella   spp   (2/12.5%)  and   Proteus 
mirabilis (14/11.8%) (Table 1). 
 
TABLE 1: PREVALENCE OF ESBL PRODUCERS AT ATKH, KANO. 
 
Isolates No. screened No. of  confirmed ESBLs % confirmed ESBLs 
E. coli 247 47 19.3 
P. mirabilis 119 14 11.8 
K.  pneumonia 50 10 20 
Ps. Aeruginosa 66 1 1.5 
Salmonella spp. 16 2 12.5 
Shigella spp. 2 1 50 
Total 500 75 15 
 
Plasmid mediated AmpC producing Isolates 
The overall prevalence of  AmpC β-lactamases was 
10%.   Highest   prevalence  was   found   among   K. 
pneumoniae (2/4.0%), followed in that order by E. coli 
 
(7/2.8%) and  P.       mirabilis  (1/0.8%). Amp  C  Beta 
lactamases were not detected among Shigella spp., 
Salmonella spp. and Ps. aeruginosa isolates (Table 2). 
 
TABLE 2: PREVALENCE OF AMP C BETA LACTAMASE PRODUCERS AT AKTH, KANO. 
 
Isolates No. screened No. of confirmed Amp C % confirmed Amp C 
E. coli 247 7 2.8 
P.  mirabilis 119 1 0.8 
K.  pneumonia 50 2 4.0 
Ps. Aeruginosa 66 0 0.0 
Salmonella spp. 16 0 0.0 
Shigella spp. 2 0 0.0 
Total 500 10 2.0 
 
 
Distributions of β-lactamases 
The  distribution of  ESBL  and  AmpC  producers in 
clinical   samples,   clinics/wards   and   sexes   were 
presented  in  Table  3,  4  and  5  respectively. ESBL 
producers were most prevalent in blood (14/22.2%) 
and urine samples (48/17.6%). This was followed in 
that order by stool (3/15.8%), urogenital swabs 
(1/14.3%) and wound swab (5/13.5%) while the least 
prevalence was observed in ear swab specimens 
(2/3.2%) (Table 3). However, AmpC was more 
prevalent in urine and catheter tips. 
Antimicrobial Susceptibility Testing 
 
Antimicrobial susceptibility of ESBL producers to the 
selected antibiotics showed that both the ESBL and 
AmpC producing isolates showed appreciable 
susceptibility to carbapenem (Imipenem) and 
flouroquinolones (Lev,  Cip,  Nit  and  Nal).  E.  coli 
producing ESBLs are more susceptible to IMI (40/47), 
followed by LEV (32/47), Nal (30/47), NIT (26/47) 
and OFL (25/47). Resistance to penicillin and 2nd and 
3rd  generation cephalosporin were high but total in 
CAZ, CHL and TET. However, ESBL producing K. 















No. and % of  ESBLs 
 
No and % of AmpC 
Ear Swab 2 (3.2) 1(10) 







































The  highest prevalence of  ESBLs  from  the  various 
clinical sections/units at the AKTH, Kano was 
recorded at the nephrology, dialysis and surgical 
outpatient units (100%) while Ear, Nose and Throat 
clinic (5.6%) had the least prevalence (Table 4). AmpC 
producers also showed similar pattern of ESBL with 
highest prevalence in ICU, SCBU, MSW and SOPD. 
The distribution of ESBL and AmpC producers based 
on gender indicates that males had a higher 
prevalence rate (37/15.3%) than females (38/14.7%) 
(Table 5). 
Moreover,  Ps.   aeruginosa  and   K.   pneumoniae  also 
showed  same  pattern  of  susceptibility profile  with 
more susceptibility to carbapenem and 
flouroquinolones (fig 2 & 3) and total resistance to 


































Clinical wards No. No. and % of ESBLs  No. and % AmpC 
GOPD 168 22(13.1)  1(0.6) 


























































































































































Key : GOPD General Out-Patient Department;  POPD Paediatrics Out-Patient Department; A&E Accident  and Emergency; ENT Ear ,Nose and 
Throat Clinic; MMW Male Medical Ward; MOPD Medical Out-Patient Department ; SCBU Special Care Baby Unit; FMW Female Medical Ward;  
NEOCLINIC Neonatal ward; MSW Male Surgical  Ward; RETAINERSHIP Microbiology Laboratory 
;SOPD  Surgical  Out-Patient  Department  ;FSSW  Female  Surgical  Speciality  Ward ;  EPU  Emergency  Paediatrics  Unit;  PMW Paediatrics  
Medical  Ward;  ANC  Antenatal  Clinic;  OPD  Out  Patient  Department  ;PNW  Post  Natal  Ward;  NEUROLOGY Neurology; DIALYSIS ;ICU 



































No. & % confirmed ESBLs 
 
 
No. & % confirmed AmpC 
Male 39 (52) 6 (60) 






























Fig1. Antibiotic susceptibility profile of 47 ESBL producing E. coli to commonly used antibiotics in a tertiary health care in 

































Fig 2. Antibiotic susceptibility profile of ESBL producing K. pneumoniae to commonly used antibiotics in a tertiary health care 
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Fig 3: Antibiotic susceptibility profile of ESBL producing P. aeruginosa to commonly used antibiotics in a tertiary health care in 




While AmpC producing E. coli are sensitive to IMI, LEV, CIP, NAL, and OFL (fig 4), AmpC producing K. pneumoniae are more 


































Fig 4: Antibiotic susceptibility profile of AmpC producing E. coli to commonly used antibiotics in a tertiary health care in Kano, 












































Fig 5. Antibiotic susceptibility profile of AmpC producing K. pneumoniae to commonly used antibiotics in a tertiary health care 




Multi drug-resistant (MDR) Gram negative bacilli 
induced infections have been reported with an 
increasing frequency in tertiary health care providers 
in Nigeria and they have been found to be associated 
with a significant morbidity and mortality [11]. The 
numerous β-  lactamases such  as  ESBL  and  AmpC 
were encoded either by the chromosomal genes or by 
the transferable genes which are located on the 
plasmids or the transposones [12]. The overall 
prevalence  of  ESBL  and  AmpC  producers  in  this 
study was 15% and 10% respectively (table 1,2). 
Although an increase in ESBL production have been 
reported in previous studies [13, 14], our results 
showed comparatively higher overall levels of ESBL- 
and AmpC producers.    Among the Gram negative 
bacteria screened for ESBL production, Shigella spp. 
had the highest prevalence (50%). This could be 
attributed to  the  fact  that  the  bacterium has  been 
progressively acquiring resistance to several 
antimicrobial agents used for the treatment of 
infections [15]. Although the number of the isolates 
recovered during the study was 2, but several reports 
have indicated an increase in cases of Shigella species 
resistant to  beta-lactams, including third-generation 
cephalosporins [15]. 
 
Comparison of  the  prevalence rate  of  ESBLs (15%) 
found in this study with findings of similar studies 
from same state indicated that the prevalence rate in 
the present study is higher when compared to 
previous studies by Yusha’u et al. [14, 16] who 
reported prevalence of 9.25% and 10.31% in 2007 and 
2009  respectively, but  lower to  reports from  other 
parts of the country, such as  Lagos, 20% [17], Benin 
36.6% and Enugu 44.6% [18]. This variations could be 
due to the differences in selecting type of antibiotic, 
antibiotic selection pressure, local antibiotic and 
prescribing habits, which differ from state to  state, 
country to country and from institution to institution. 
 
Among the clinical specimens, blood (22.2%) had the 
highest prevalence of  ESBL producers followed by 
urine (17.6%). This observation is in agreement with 
that  of  Osazuwa et  al.  [18]  who  found  that  ESBL 
prevalence was highest for blood (61.2%) and urine 
(16.41%)  specimens.  This   might  be   attributed  to 
factors like improper use of syringes or needles, 
inadequate disinfection of skin of prolonged hospital 
stayed patients during phlebotomy or transfusion, 
poor  hand  washing  techniques among  health  care 
practitioners which are some of the factors that 
predispose one to blood stream infections. 
 
The  distribution of  ESBLs  and  AmpCs  in  hospital 
sections/units was  highest in  the  nephrology, 
dialysis, surgical outpatient wards (100%) followed in 
that order by the ICU and the SCBU (50%). This 
indicates that they are more found among the 
hospitalized patients who may have contact them in 
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the hospital or from the health care providers. Some 
of these units mostly deal with seriously ill patients 
with life threatening infections and those in need of 
special postoperative techniques and  are  placed on 
prolonged  antibiotic  therapy.  High  prevalence  of 
ESBL and AmpC in ICUs in the hospital has negative 
health implications, and could result into prolonged 
hospital stay, increased cost of treatment and quick 
spread in the hospital setting. Major risk factors for 
colonization or infection with ESBL and AmpC 
producing organisms are long term antibiotic 
exposure, prolonged ICU stay, nursing home 
residency, severe illness, residence in  an  institution 
with high rates of third generation cephalosporin use 
and  instrumentation or  catheterization [19].  AKTH 
being a tertiary care that served as referral center for 
other hospitals within and outside the metropolis, it 
received many patients from various government 
owned and private owned hospitals with varying 
complicated life threatening infections. This has lead 
to  use  of  higher  antibiotics by  the  clinicians  as  a 
common  empirical  therapy  without  screening  for 
ESBL  and  or  AmpC.  In  addition,  due  to  heavy 
patients load from other hospitals, proper infection 
control measures cannot be maintained by the 
paramedical staffs which can lead to transfer of MDR 
to  other  hospital.  All  of  these  factors  lead  to  the 
higher  rate  of  ESBL  and  AmpC β-lactamase 
producing organisms in our institution. 
 
Based on gender, the distribution of the duo was not 
statistically significant as prevalence of 52 and 48.7% 
was recorded for ESBLs while 60% and 40% was 
recorded  for  AmpC  beta  lactamase  (P<0.05). 
However, in another study, Erum et al. [20] reported 
increased ESBL production in males as compared to 
females. It  was  hypothesized that males in  general 
have more obstructive uropathies leading to frequent 
urinary catheterization and have more chronic 
pulmonary and cardiovascular diseases that in turn 
lead to increased hospitalization and higher 
prevalence. 
 
The distribution of antibiotic resistance to ß-lactams 
in this study was very similar to that described by 
Stéphane et al. [21] with nearly all of the isolates being 
resistant or slightly susceptible         to commonly 
prescribed antibiotics in the hospitals, and many of 
the  isolates  showing  a  decreased  susceptibility or 
resistance to promising antibiotics such as imipenem, 
levofloxaxin, cefoxitin, cefpodoxime and  ceftriaxone 
(fig 1). The study showed that imipenem and 
levofloxacin were still  the  most effective antibiotics 
against ESBL and Amp C beta lactamase producing 
bacteria. However, data showed that imipenem usage 
in the hospital is low when compared with 
levofloxacin. Thus, these drugs could be used to treat 
infections caused by  bacteria capable of  producing 
these enzymes especially in cases of life-threatening 
infections such as urinary tract infections and 
pulmonary pneumonia. However, unless antibiotic 
therapy is restricted and controlled legally, misuse in 
the form of self medication may cause the spread of 
resistance, which will result in the prevalence of 
resistance against effective antibiotics such as 




Based  on  the  findings  of  this  study,  it  could  be 
deduced that: 
 
• Prevalence of ESBL and AmpC Betalactamases 
producing gram negative bacteria is on the 
increase in  a  tertiary  health  care  in  Kano 
North West Nigeria. 
• Blood  and  urine     samples  had  a   higher 
prevalence of ESBL producers in Kano 
• The  resistant  pathogens  were  more  found 
Neurology, dialysis and surgical out patient 
clinical sections/ units         in addition to 
intensive care units. 
• Prevalence of  ESBL  and  AmpC producing 
bacteria does not differ significantly between 
the sexes. 
• Levofloxacin    and    Imipenem    is    choice 
antibiotic for the treatment of infections 
caused by ESBL and Amp C producing 
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